Depomed Reports Third Quarter 2011 Financial Results

MENLO PARK, Calif., Nov 1, 2011 (GlobeNewswire via COMTEX) -- Depomed, Inc. /quotes/zigman/63635/quotes/nls/depo DEPO +6.39% today reported financial results for the third quarter ended September 30, 2011 and provided an update on the company's business.

"With the launch of Gralise in October, we've taken a major step in our strategic vision to become a profitable specialty pharmaceutical company initially focused on neurology. We are pleased with the Gralise launch and market uptake. Our highly trained and experienced sales force and field organization are executing well, and early prescription data are strong. The reception from managed care is positive, with coverage exceeding our expectations," said Jim Schoeneck, Depomed's president and CEO.

"Another key accomplishment during the third quarter was restructuring our promotion agreement with Santarus for Glumetza, which we believe will translate into greater income potential for Depomed as Santarus grows the product."

"Relative to our menopausal hot flash product candidate Serada, we are continuing to evaluate our options in light of our recently announced Breeze 3 clinical trial results. We plan to meet with the FDA as soon as the first quarter of 2012 to determine whether there is a path to registration.

"Today, Depomed is a growing commercial business and has a strong balance sheet with over $150 million in cash that can facilitate transactions to accelerate our growth. I believe Depomed's future as an integrated specialty pharma company is very bright, and that we are well-positioned to execute our strategies," said Schoeneck.

The company's third quarter results reflect a new commercialization agreement for Glumetza (extended release metformin hydrochloride tablets) entered into with Santarus, Inc. in August 2011. Under terms of the agreement, Santarus began booking Glumetza product sales in September while paying Depomed a royalty on net sales of 26.5% for the remainder of 2011 with the rate increasing to 29.5% in 2012, 32.0% in 2013 and 2014, and 34.5% in 2015 and beyond.

Financial Results

Total revenues for the quarter were $16.5 million compared to $20.1 million for the third quarter of 2010. Revenues for the third quarter of 2011 included two months of Glumetza product sales and one month of royalties on Glumetza product sales made by Santarus. Revenues for the third quarter of 2010 included the one-time recognition of $6 million in milestone payments under development and license arrangements with Janssen Pharmaceutica and Covidien. Net loss for the quarter was $8.6 million, or $0.15 per share, compared to net income of $1.9 million, or $0.04 per share, for the third quarter of 2010.

Cash, cash equivalents and marketable securities were $154.2 million as of September 30, 2011 compared to $76.9 million as of December 31, 2010.

During the quarter, the company distributed and recorded product sales of Glumetza for the first two months of the quarter and then transitioned the distribution of Glumetza to Santarus under the new commercialization agreement. Santarus distributed and recorded product sales of Glumetza for the final month of the quarter. The company recorded Glumetza product sales of $9.2 million, Glumetza cost of goods sold of $0.8 million and promotion fee expense to Santarus of $6.0 million during the third quarter of 2011, which represents two months of Depomed's sales of Glumetza under the prior promotion agreement with Santarus. Under the new commercialization agreement with Santarus, the company recorded Glumetza royalties of $2.1 million during the third quarter of 2011, which represents one month of royalties on Santarus' sales of Glumetza. Glumetza product sales recognized by Depomed for the quarter reflects a $3.5 million increase in sales return reserve during the quarter resulting from a Glumetza price increase taken in August 2011. In the corresponding quarter of the prior year, Glumetza product sales were $9.8 million, Glumetza cost of goods sold was $2.5 million and promotion fee expense to Santarus was $6.8 million.

License and collaborative revenue for the third quarter of 2011 was $5.1 million, compared to $10.2 million for the third quarter of 2010. The decrease in license and collaborative revenue was primarily due to the one-time milestones from Janssen and Covidien recognized in the third quarter of 2010.

Total operating expenses for the quarter were $24.7 million, compared to $15.7 million for the comparable quarter of 2010.

Selling, general and administrative expense for the third quarter of 2011 was $21.5 million, compared to $11.1 million for the third quarter of 2010. The increase in selling, general and administrative expense was primarily due to sales and marketing costs related to the launch of Gralise in October.

Conference Call

Depomed will host a conference call today, Tuesday, Nov 1, beginning at 5:00 p.m. eastern time, 2:00 p.m. pacific time, to discuss its results. The conference call will be available via a live webcast on the investor relations section of Depomed's website at .

The conference call will be available via a live webcast and via telephone. The dial-in number from the United States and Canada is 888-778-9067 and the conference code is 8045250. For calls from other countries, the dial-in number is 913-312-0408.

The webcast can be accessed via the investor relations section of Depomed's website at . Access the website 15 minutes prior to the start of the call to download and install any necessary audio software. An archived webcast replay will be available on the Company's website for three months.

About Depomed

Depomed, Inc. is a specialty pharmaceutical company with two approved and marketed products. Gralise (TM) (gabapentin) is a once-daily treatment approved for the management of postherpetic neuralgia (PHN). Glumetza(R) (metformin hydrochloride extended release tablets) is approved for use in adults with type 2 diabetes and promoted by Santarus, Inc. in the United States. Depomed formulates its products and product candidates with its proven, proprietary Acuform(R) drug delivery technology, which is designed to improve existing oral medications, allowing for extended release of medications to the upper gastrointestinal tract when dosed with food. Additional information about Depomed may be found on its website, .

The Depomed, Inc. logo is available at

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995.

Statements included in this press release that are not a description of historical facts are forward-looking statements. These forward-looking statements include statements related to the launch of Gralise, the conclusion of the Breeze 3 clinical trial and future royalties from Glumetza. The inclusion of forward-looking statements should not be regarded as a representation that any of the company's plans or objectives will be achieved. The achievement of those plans and objectives involves risks and uncertainties including, but not limited to, risks and uncertainties related to the launch and market acceptance of Gralise; regulation by the FDA and other government agencies; the timing of regulatory applications and product launches; and other risks detailed in the company's Securities and Exchange Commission filings, including the company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

(in thousands, except share and per share amounts)

Three Months Ended Nine Months Ended
September 30, September 30,
---------------------- ----------------------

2011 2010 2011 2010
---------- ---------- ---------- ----------
Product sales $9,205 $9,829 $40,669 $34,086
Royalties 2,179 75 2,412 254
License and collaborative
revenue 5,138 10,223 77,760 25,565
---------- ---------- ---------- ----------
Total revenues 16,522 20,127 120,841 59,905

Costs and expenses:
Cost of sales 1,150 2,499 4,925 6,961
Research and development
expense 3,208 4,602 12,405 14,360
Selling, general and
administrative expense:
Promotion fee expense 6,023 6,791 27,339 23,769
Other selling, general and
administrative expense 15,451 4,313 32,667 12,403
---------- ---------- ---------- ----------
Total selling, general and
administrative expense 21,474 11,104 60,006 36,172

Gain on settlement agreement -- -- (40,000) --
---------- ---------- ---------- ----------

Total costs and expenses 25,832 18,205 37,336 57,493
---------- ---------- ---------- ----------

Income (loss) from operations (9,310) 1,922 83,505 2,412

Other income (expense):
Interest and other income 410 100 846 251

Interest expense (24) (130) (133) (471)
---------- ---------- ---------- ----------
Total other income (expense) 386 (30) 713 (220)

Net income (loss) before income
taxes (8,924) 1,892 84,218 2,192

Provision for income taxes 348 (1) 345 (4)
---------- ---------- ---------- ----------

Net income (loss) $(8,576) $1,891 $84,563 $2,188
========== ========== ========== ==========

Basic net income (loss) per
common share $(0.15) $0.04 $1.56 $0.04
Diluted net income (loss) per
common share $(0.15) $0.04 $1.51 $0.04

Shares used in computing basic
net income (loss)
per common share 55,371,954 52,595,214 54,267,829 52,444,627
Shares used in computing diluted
net income (loss)
per common share 55,371,954 53,306,449 56,071,870 53,061,251


(in thousands, except share amounts)

September December
30, 31,

2011 2010
----------- ---------
(Unaudited) (1)
Current assets:
Cash and cash equivalents $19,945 $22,526
Marketable securities 89,018 47,825
Accounts receivable 827 6,094
Receivables from collaborative
partners 6,645 253
Inventories 3,292 1,571
Prepaid and other current
assets 5,516 1,330
----------- ---------
Total current assets 125,243 79,599
Marketable securities, long-term 45,233 6,537
Property and equipment, net 1,140 698

Other assets 169 197
----------- ---------

$171,785 $87,031
=========== =========
Current liabilities:
Accounts payable and accrued
liabilities $25,788 $18,473
Deferred product sales 379 1,041
Deferred license revenue 7,664 10,665
Other current liabilities 387 635
Current portion of long-term
debt -- 2,170
----------- ---------
Total current liabilities 34,218 32,984
Deferred license revenue,
non-current portion 19,320 30,926
Other long-term liabilities -- 15
Shareholders' equity:
Preferred stock, no par value,
5,000,000 shares authorized;
Series A
convertible preferred stock,
25,000 shares designated,
18,158 shares issued
and surrendered, and zero
shares outstanding at
September 30, 2011 and
December 31, 2010 -- --
Common stock, no par value,
100,000,000 shares authorized;
and 52,957,787 shares issued
and outstanding at September
30, 2011 and December 31,
2010, respectively 202,022 191,343
Accumulated deficit (83,743) (168,306)
Accumulated other comprehensive
gain (loss) (32) 69
----------- ---------

Total shareholders' equity 118,247 23,106
----------- ---------

$171,785 $87,031
=========== =========

(1) Derived from the audited financial statements
included in the Company's Annual Report on Form 10-K
for the year ended December 31, 2010.


This news release was distributed by GlobeNewswire,

SOURCE: Depomed, Inc.



Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.